Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Operating Margin (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Operating Margin for 11 consecutive years, with 5423.38% as the latest value for Q4 2025.

  • Quarterly Operating Margin rose 190151.0% to 5423.38% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 275778.85% through Dec 2025, up 27589330.0% year-over-year, with the annual reading at 35851.25% for FY2025, 3573844.0% down from the prior year.
  • Operating Margin for Q4 2025 was 5423.38% at Cartesian Therapeutics, up from 7319.13% in the prior quarter.
  • The five-year high for Operating Margin was 5423.38% in Q4 2025, with the low at 7319.13% in Q2 2025.
  • Average Operating Margin over 5 years is 105.71%, with a median of 29.32% recorded in 2021.
  • The sharpest move saw Operating Margin surged 396141bps in 2024, then plummeted -736048bps in 2025.
  • Over 5 years, Operating Margin stood at 13.62% in 2021, then tumbled by -471bps to 50.59% in 2022, then plummeted by -769bps to 439.54% in 2023, then skyrocketed by 901bps to 3521.87% in 2024, then soared by 54bps to 5423.38% in 2025.
  • According to Business Quant data, Operating Margin over the past three periods came in at 5423.38%, 7319.13%, and 1989.91% for Q4 2025, Q2 2025, and Q1 2025 respectively.